- Home
- BMEA vs BMR Comparison
BMEA vs BMR Comparison
Compare BMEA & BMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BMEA
- BMR
- Stock Information
- Founded
- BMEA 2017
- BMR 2009
- Country
- BMEA United States
- BMR Israel
- Employees
- BMEA N/A
- BMR N/A
- Industry
- BMEA Biotechnology: Pharmaceutical Preparations
- BMR Computer Software: Prepackaged Software
- Sector
- BMEA Health Care
- BMR Technology
- Exchange
- BMEA Nasdaq
- BMR Nasdaq
- Market Cap
- BMEA 65.8M
- BMR 59.3M
- IPO Year
- BMEA 2021
- BMR 2023
- Fundamental
- Price
- BMEA $1.73
- BMR $2.63
- Analyst Decision
- BMEA Strong Buy
- BMR
- Analyst Count
- BMEA 11
- BMR 0
- Target Price
- BMEA $27.60
- BMR N/A
- AVG Volume (30 Days)
- BMEA 713.5K
- BMR 57.0K
- Earning Date
- BMEA 05-05-2025
- BMR 05-20-2025
- Dividend Yield
- BMEA N/A
- BMR N/A
- EPS Growth
- BMEA N/A
- BMR N/A
- EPS
- BMEA N/A
- BMR N/A
- Revenue
- BMEA N/A
- BMR $3,064,000.00
- Revenue This Year
- BMEA N/A
- BMR N/A
- Revenue Next Year
- BMEA N/A
- BMR N/A
- P/E Ratio
- BMEA N/A
- BMR N/A
- Revenue Growth
- BMEA N/A
- BMR 5.33
- 52 Week Low
- BMEA $1.53
- BMR $1.86
- 52 Week High
- BMEA $13.43
- BMR $6.71
- Technical
- Relative Strength Index (RSI)
- BMEA 41.85
- BMR 58.10
- Support Level
- BMEA $1.61
- BMR $2.57
- Resistance Level
- BMEA $2.30
- BMR $2.89
- Average True Range (ATR)
- BMEA 0.20
- BMR 0.19
- MACD
- BMEA -0.00
- BMR 0.05
- Stochastic Oscillator
- BMEA 21.74
- BMR 82.23
About BMEA Biomea Fusion Inc.
Biomea Fusion Inc is a clinical-stage diabetes and obesity medicines company focused on the discovery and development of oral covalent small-molecule drugs to treat patients with metabolic diseases. The company uses its proprietary FUSION System discovery platform to develop a pipeline of novel small-molecule product candidates. Its principal clinical program's drug candidate, icovamenib, is being developed as an orally bioavailable, selective covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity. The company is also developing BMF-650, an investigational, oral small-molecule GLP-1 RA, which has the potential to be a therapeutic option for diabetes and obesity.
About BMR Beamr Imaging Ltd.
Beamr Imaging Ltd is a video technology and image science software company. It is an innovator of video encoding, transcoding, and optimization solutions that enable high quality, performance, and unmatched bitrate efficiency for video and images. The company is conducted through one operating segment, the optimization technology for video and photo compression. The company operates in Israel, the United States, and the rest of the world, it derives a majority of its revenue from the United States.